S

Synlogic
D

SYBX

1.33000
USD
-0.05
(-3.62%)
Market Closed
Volume
0
EPS
-7
Div Yield
-
P/E
-1
Market Cap
15,555,825
Related Instruments
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    A
    ACRS
    -0.08000
    (-3.45%)
    2.24000 USD
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    A
    AMRN
    -0.00130
    (-0.22%)
    0.58930 USD
    A
    ARDX
    -0.65000
    (-11.39%)
    5.05500 USD
    A
    AVDL
    -0.05500
    (-0.65%)
    8.41000 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    M
    MYGN
    -0.790
    (-5.27%)
    14.190 USD
    More
News

Title: Synlogic

Sector: Healthcare
Industry: Biotechnology
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.